Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
SGN-35C in Hodgkin's Lymphoma: NCT06254495 Clinical Landscape Report 2026
16 October 2026
NCT06254495 clinical landscape for Hodgkin's Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nogapendekin alfa inbakicept-pmln in Mismatch repair-deficient Endometrial Carcinoma: NCT06253494 Clinical Landscape Report 2026
16 October 2026
NCT06253494 clinical landscape for Mismatch repair-deficient Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Aminolevulinic Acid Hydrochloride in Soft Tissue Sarcoma: NCT06252727 Clinical Landscape Report 2026
16 October 2026
NCT06252727 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Refractory Melanoma: NCT06250335 Clinical Landscape Report 2026
16 October 2026
NCT06250335 clinical landscape for Refractory Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SPX-303 in Squamous Cell Carcinoma of Head and Neck: NCT06259552 Clinical Landscape Report 2026
16 October 2026
NCT06259552 clinical landscape for Squamous Cell Carcinoma of Head and Neck: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Fulvestrant in Endometrial Carcinoma: NCT06257264 Clinical Landscape Report 2026
16 October 2026
NCT06257264 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GM-103 in Locally Advanced Malignant Solid Neoplasm: NCT06265025 Clinical Landscape Report 2026
16 October 2026
NCT06265025 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Gemcitabine Hydrochloride in Triple Negative Breast Cancer: NCT06268327 Clinical Landscape Report 2026
16 October 2026
NCT06268327 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vusolimogene oderparepvec-wtpg in Melanoma: NCT06264180 Clinical Landscape Report 2026
16 October 2026
NCT06264180 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IK-595 in Advanced Malignant Solid Neoplasm: NCT06270082 Clinical Landscape Report 2026
16 October 2026
NCT06270082 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
NKT-3447 in Human epidermal growth factor 2 negative carcinoma of breast: NCT06264921 Clinical Landscape Report 2026
16 October 2026
NCT06264921 clinical landscape for Human epidermal growth factor 2 negative carcinoma of breast: endpoints, sponsor, phase, geography, readouts, asset contex…
9 min read
AM-003 (Aummune) in Locally Advanced Malignant Solid Neoplasm: NCT06258330 Clinical Landscape Report 2026
16 October 2026
NCT06258330 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…